Molecule

Cyclophosphamide

Also known as cyclophosphamide anhydrous

Available on requestCold chainOncology

Presentations: 18
Brands: 1
Manufacturers: 1
Available from stock: 0

Cyclophosphamide is a prescription medicine indicated for treatment of malignant Diseases, among other approved uses. It is available as powder for injection, injection and capsules for intravenous and oral use. MedsAcross supplies Cyclophosphamide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Key facts

ATC classification: L01AA01 Cyclophosphamide · Nitrogen mustard
US FDA first approval: 16 November 1959
EU status: Not recorded
Orphan designation: Not recorded
WHO essential medicine: Not recorded
India (CDSCO): Not yet confirmed against CDSCO approval lists
Routes: Intravenous, Oral
Dosage forms: Powder for injection, Injection, Capsule, Tablet
Identifiers: UNII 6UXW23996MRxCUI 3002CAS 50-18-0DrugBank DB00531Q408524

Clinical information

From the regulator-approved product information. Each section names its source.

Uses

Cyclophosphamide Tablets is an alkylating drug indicated for treatment of: • Malignant Diseases: malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma, multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma. • Minimal Change Nephrotic Syndrome in Pediatric Patients: biopsy proven minimal change nephrotic syndrome patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy. Limitations of Use: The safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established.

Source: US FDA prescribing information

How it works

The mechanism of action is thought to involve cross-linking of tumor cell DNA.

Source: US FDA prescribing information

Dosing overview

During or immediately after the administration, administer adequate amounts of fluid to reduce the risk of urinary tract toxicity. Malignant Diseases: Adult and Pediatric Patients • Oral: Usually 1 mg per kg to 5 mg per kg once daily for both initial and maintenance dosing. Minimal Change Nephrotic Syndrome in Pediatric Patients • Recommended oral dose: 2 mg per kg once daily for 8 to 12 weeks (maximum cumulative dose 168 mg per kg). Treatment beyond 90 days increases the probability of sterility in males.

Source: US FDA prescribing information

Contraindications

Cyclophosphamide Tablets are contraindicated in patients with: • A history of severe hypersensitivity reactions to cyclophosphamide, any of its metabolites, or to other components of the product. Anaphylactic reactions including death have been reported with cyclophosphamide. Cross-sensitivity with other alkylating agents can occur. • In patients with urinary outflow obstruction. • Hypersensitivity to cyclophosphamide. • Urinary outflow obstruction

Source: US FDA prescribing information

Warnings and precautions

• Myelosuppression, Immunosuppression, Bone Marrow Failure and Infections – Severe immunosuppression may lead to serious and sometimes fatal infections. Close hematological monitoring is required. • Urinary Tract and Renal Toxicity – Hemorrhagic cystitis, pyelitis, ureteritis, and hematuria can occur. Exclude or correct any urinary tract obstructions prior to treatment. • Cardiotoxicity – Myocarditis, myopericarditis, pericardial effusion, arrythmias and congestive heart failure, which may be fatal, have been reported. Monitor patients, especially those with risk factors for cardiotoxicity or pre-existing cardiac disease. • Pulmonary Toxicity – Pneumonitis, pulmonary fibrosis and pulmonary veno-occlusive disease leading to respiratory failure may occur. Monitor patients for signs and symptoms of pulmonary toxicity. • Secondary malignancies.

Source: US FDA prescribing information

Side effects

The following adverse reactions are discussed in more detail in other sections of the labeling. • Hypersensitivity • Myelosuppression, Immunosuppression, Bone Marrow Failure, and Infections • Urinary Tract and Renal Toxicity • Cardiotoxicity • Pulmonary Toxicity • Secondary Malignancies • Veno-occlusive Liver Disease • Infertility • Impaired Wound Healing • Hyponatremia Adverse reactions reported most often include neutropenia, febrile neutropenia, fever, alopecia, nausea, vomiting, and diarrhea.

Source: US FDA prescribing information

Interactions

Cyclophosphamide is a pro-drug that is activated by cytochrome P450s. An increase of the concentration of cytotoxic metabolites may occur with: • Protease inhibitors: Concomitant use of protease inhibitors may increase the concentration of cytotoxic metabolites. Use of protease inhibitor-based regimens was found to be associated with a higher Incidence of infections and neutropenia in patients receiving cyclophosphamide, doxorubicin, and etoposide (CDE) than use of a Non-Nucleoside Reverse Transcriptase Inhibitor-based regimen. Combined or sequential use of cyclophosphamide and other agents with similar toxicities can potentiate toxicities.

Source: US FDA prescribing information

Storage

Store tablets at 20°C to 25°C (68°F to77°F), excursions permitted between 15°C to 30°C (59°F to 86°F).

Source: US FDA prescribing information

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

All presentations

18 presentations of Cyclophosphamide, sorted by availability.

Medicine	Manufacturer	Register	Availability
Cyclophosphamide 1 g/50 mL powder for injectionIntravenous, oralGeneric name	—	US FDA	Available on request
Cyclophosphamide 1 g/50 mL powder for injectionIntravenousGeneric name	—	US FDA	Available on request
Cyclophosphamide 25 mg capsuleOralGeneric name	—	US FDA	Available on request
Cyclophosphamide 50 mg capsuleOralGeneric name	—	US FDA	Available on request
Cyclophosphamide 1000 mg/5 mL injectionIntravenous Cold chainGeneric name	—	US FDA	Available on request
Cyclophosphamide 500 mg/2.5 mL injectionIntravenous Cold chainGeneric name	—	US FDA	Available on request
Cyclophosphamide 2000 mg/10 mL injectionIntravenous Cold chainGeneric name	—	US FDA	Available on request
Cyclophosphamide 1 g/2 mL injectionIntravenous Cold chainGeneric name	—	US FDA	Available on request
Cyclophosphamide 1000 mg/10 mL injectionIntravenous Cold chainGeneric name	—	US FDA	Available on request
Cyclophosphamide 2 g/4 mL injectionIntravenous Cold chainGeneric name	—	US FDA	Available on request
Cyclophosphamide 2000 mg/20 mL injectionIntravenous Cold chainGeneric name	—	US FDA	Available on request
Cyclophosphamide 25 mg tabletOralGeneric name	—	US FDA	Available on request
Cyclophosphamide 50 mg tabletOralGeneric name	—	US FDA	Available on request
Cyclophosphamide 500 mg/1 mL injectionIntravenous Cold chainGeneric name	—	US FDA	Available on request
Cyclophosphamide 500 mg/5 mL injectionIntravenous Cold chainGeneric name	—	US FDA	Available on request
Frindovyx 1 g/2 mL injectionIntravenous Cold chain	Avyxa Pharma	US FDA	Available on request
Frindovyx 2 g/4 mL injectionIntravenous Cold chain	Avyxa Pharma	US FDA	Available on request
Frindovyx 500 mg/1 mL injectionIntravenous Cold chain	Avyxa Pharma	US FDA	Available on request

Brands by market

1 brand names across 1 markets.

Brand names by country

United States

Frindovyx

Manufacturers

Avyxa Pharma3 presentations

Regulatory status

Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.

Register	Status	Source
US FDA	First approved 16 November 1959	Drugs@FDA
EU (EMA)	Not recorded	—
India (CDSCO)	Not yet confirmed against CDSCO approval lists	—
United States	Registered	US FDA (NDC directory, openFDA)Checked 12 November 2026

Conditions

Conditions linked to Cyclophosphamide in public data. This is not a list of approved uses, see the clinical information.

Questions and answers

Is Cyclophosphamide available for export from India?

Yes, on request. MedsAcross lists 18 presentations of Cyclophosphamide and sources them for licensed hospitals, importers and physicians against valid import documents.

What brand names does Cyclophosphamide have?

The catalogue lists 1 brand names for Cyclophosphamide, including Frindovyx.

Is Cyclophosphamide approved by the US FDA?

Yes. The US FDA first approved Cyclophosphamide on 16 November 1959, according to Drugs@FDA.

Does Cyclophosphamide need cold chain shipping?

At least one listed presentation of Cyclophosphamide must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.

Which ATC class is Cyclophosphamide in?

Cyclophosphamide is classified under ATC code L01AA01 (Cyclophosphamide).

References

Cyclophosphamide prescribing information (Baxter Healthcare). U.S. National Library of Medicine, DailyMed. Retrieved 7 August 2020

Request Cyclophosphamide for export supply

Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.

Request a quote Read the import guides